Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Drugs in Context

article

Xenophon Kassianides¹  Sunil Bhandari¹  M Clin Edu¹ 

[1] Department of Academic Renal Research, Hull University Teaching Hospitals NHS Trust, 2nd Floor Alderson House, Hull Royal Infirmary, Anlaby Road

关键词: ferric carboxymaltose;    ferric derisomaltose;    ferumoxytol;    fibroblast growth factor 23;    hypophosphataemia;    intravenous iron;    iron-deficiency anaemia;    safety;   

DOI  :  10.7573/dic.2020-11-3

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Third-generation intravenous (i.v.) iron preparations are safe and efficacious and are increasingly used in the treatment of iron-deficiency anaemia. Hypophosphataemia is emerging as an established side-effect following the administration of certain compounds. Symptoms of hypophosphataemia can be masked by their similarity to those of iron-deficiency anaemia and both acute and chronic hypophosphataemia can be detrimental. Hypophosphataemia appears to be linked to imbalances in the metabolism of the phosphatonin fibroblast growth factor 23. In this narrative review, we discuss the possible pathophysiology behind this phenomenon, the studies comparing third-generation i.v. iron compounds, and the potential implications of the changes in fibroblast growth factor 23 and hypophosphataemia. We also present an algorithm of how to approach such patients requiring i.v. iron in anticipation of hypophosphataemia and how the impact related to it can be minimized.

【 授权许可】

CC BY-NC-ND